UK
Health analytics
Health equity
We work with our clients to navigate this complex issue, helping identify and implement tractable measures to embed health equity considerations across clinical development through to access to medicines to reduce inequalities and improve population health.
Why is health equity important?
Despite healthcare progress, inequalities in life expectancy and health outcomes have grown, both within and across countries. Socioeconomic deprivation, ethnicity, and geography all contribute to health inequalities, as well as access to medicine and good health care.
Vast inequalities in health outcomes persist in society; for example, elevated mortality rates for COPD and severe asthma are observed in lower income and rural populations with high smoking rates in the US. The link between poorer health outcomes, increased multimorbidity, and poor economic and wider societal outcomes has also become more clear.
In response, health equity is of increasing importance to federal and state governments, payers and providers. For example some payers are becoming increasingly committed to track variation in access to medicines and incorporate health equity into HTA processes.
While the largest impact on health inequalities is likely to come from public health initiatives, the life sciences sector has a substantial role to play from improving diversity in clinical trials to partnering with health care systems to enable more equitable access and uptake to medicines.
Pharmaceutical companies can play an important role, from more representative clinical trials through to collaborating with stakeholders to demonstrate how their technologies improve health equity.
Our work supports our clients in placing health equity at the heart of what they do
A core part of LCP Health Analytics’ purpose is to reduce inequalities through improving health equity
We do this via our work with clients and partners across the life sciences sector to identify tractable solutions to enact this change.
Across market access, we advise clients on key considerations to embed health equity into routine practices and how this varies according to the disease, market, population subgroup or domain of equity (e.g. income, deprivation, or ethnicity) and dataset availability.
Specifically, we help our life science clients in these key ways:
- Developing and embedding company-wide health equity strategies, from research and development through to access and uptake of new medicines or technologies
- Embed health equity in evidence generation strategies and develop real-world evidence quantifying the inequalities in unmet need across population subgroups such as according to income, deprivation, or ethnicity
- Use quantitative methods to demonstrate the equity impacts of medicines or technologies such as Distributional Cost Effectiveness Analysis cognizant of the challenges facing HTA organizations and payers in assessing such evidence
- Support market access strategies to identify and prioritize health equity activities according to commercial and market access objectives and payer landscape
- Shaping the environment through thought leadership to improve healthcare system readiness for equity initiatives and to lead the sector
We know that change requires partnerships and so at LCP we help to drive collaboration across industry, academia, and HTA organizations/payers to ensure tractable progress to improve health equity.
Explore our range of services
Real-world evidence generation
We work closely with clients to meet the growing demand for rigorous and impactful real world evidence.
Health economic outcomes research
We support you in thoroughly evaluating and clearly communicating your product’s value.
Global market access strategy
We help you navigate uncertainty and maximize value across product development and commercialization.
US access solutions
We provide integrated US market access solutions using analytics, clinical insight, and strategic consulting to support pharma success.
Medical and public affairs
We empower medical and public affairs teams to identify and act on opportunities for health system transformation.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
Get in touch
Contact us to learn more about how we can provide clarity and insight in today’s increasingly complex life sciences and healthcare environment.
